Tandem Diabetes Care 

$44.7
60
+$0.88+2.01% Friday 20:00

统计数据

当日最高
44.89
当日最低
43.58
52周最高
53.69
52周最低
13.82
成交量
832,812
平均成交量
1,987,399
市值
2.93B
市盈率
-21.39
股息收益率
-
股息
-

即将到来

收益

30Oct已确认
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
下一个
-1.92
-1.37
-0.82
-0.27
预期每股收益
-0.411666
实际每股收益
N/A

人们还关注

此列表基于关注TNDM的Stock Events用户的观察列表。这不是投资建议。

竞争者

这个列表是基于最近市场事件的分析。这不是投资建议。
Dexcom
DXCM
市值29.91B
Dexcom生产连续血糖监测系统,与Tandem的胰岛素泵直接竞争,处于糖尿病管理领域。
Insulet
PODD
市值12.76B
Insulet Corporation提供Omnipod,这是一种与Tandem的胰岛素泵产品竞争的胰岛素管理系统。
Medtronic
MDT
市值108.51B
Medtronic是糖尿病护理市场的主要参与者,提供与Tandem竞争的胰岛素泵和持续血糖监测系统。
Abbott Laboratories
ABT
市值193.13B
Abbott Laboratories生产FreeStyle Libre,这是一种连续血糖监测系统,在更广泛的糖尿病管理市场上竞争。
Senseonics
SENS
市值221.08M
Senseonics Holdings提供Eversense CGM系统,是连续血糖监测市场上的直接竞争对手。
Thermo Fisher Scientific
TMO
市值230.72B
赛默飞世尔科技公司通过其生命科学解决方案,在间接竞争糖尿病护理市场,提供支持糖尿病研究和诊断的技术和用品。
Novo Nordisk
NVO
市值457.29B
诺和诺德是一家全球领先的医疗保健公司,尽管主要以其糖尿病药物而闻名,但也投资于糖尿病护理设备和解决方案,使其成为更广泛的竞争对手。
Sanofi
SNY
市值137.19B
Sanofi通过其胰岛素和血糖监测解决方案参与糖尿病护理,使其成为糖尿病管理领域的竞争对手。
Baxter International
BAX
市值18.43B
Baxter International提供医疗设备,虽然不直接竞争胰岛素泵或CGM市场,但提供各种可用于糖尿病护理的医疗解决方案。
Johnson & Johnson
JNJ
市值383.69B
强生公司通过其医疗设备和制药业务,在糖尿病市场上有着利益,使其成为糖尿病管理领域中更广泛的竞争对手。

分析师评级

55.55$平均价格目标
最高估值为 $75。
来自过去6个月内的 11 个评级。这不是投资建议。
买入
91%
持有
9%
卖出
0%

关于

Health Technology
Medical Specialties
Manufacturing
Surgical and Medical Instrument Manufacturing
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Show more...
首席执行官
John Sheridan
员工
2400
国家
US
ISIN
US8753722037
WKN
000A2H5BX

上市公司